

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 4/2023

Date of preparation: 2023-02-09

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax, Inc.

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion of a commercial contract manufacturing agreement with Novavax, Inc. ("Novavax", "Manufacturing Agreement") and subsequent current reports regarding the expansion of the cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 9 February 2023, it signed with Novavax a further extension of the scope of services under the Manufacturing Agreement, in the form of Statement of Work #10 ("SOW#10").

SOW#10 covers logistics services, including transport and storage of materials, vaccine active substances, and finished vaccine products by the Company in appropriate transport and storage conditions agreed upon by the Parties. All these services will be rendered in a GMP-compliant environment.

The extension of services will take effect on the date of signing of the document and will remain in force until fully completed, unless the Parties jointly decide to discontinue the work under the order earlier.

The value of SOW#10 will depend on the volume of Novavax's contracted transport services and products to be stored as well as the duration of their storage by the Company. The current estimated value of the order in the first year is approximately PLN 1.2 million, although it may eventually change.